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Abstract Colorectal cancer (CRC) is the second leading
cause of cancer dead in Spain. About half the patients will
eventually develop distant metastases. However, as treat-
ment options are expanding, prognosis has steadily improved
over the last decades. Management of advanced CRC should
be discussed within an experienced multidisciplinary team to
select the most appropriate systemic treatment (chemother-
apy and targeted agents) and to integrate surgical or ablative
procedures when indicated. Disease site and extent,
resectability, tumor biology and gene mutations, clinical
presentation, patient preferences, and comorbidities are key
factors to design a customized treatment plan. The aim of
these guidelines is to provide synthetic recommendations for
managing advanced CRC patients.
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Introduction
In Spain, there were 19,261 new cases of colorectal cancer
(CRC) in men (44 cases per 100,000—third most incident
cancer site-) and 12,979 cases in women (24.2 cases per
100,000—second most incident cancer site-) in 2012. CRC
is the second cause of cancer mortality in men with 8742
deaths (13.7 % of cancer deaths) and in women with 5958
deaths (15.2 % of cancer deaths) annually [1].
The Spanish Society of Medical Oncology (SEOM)
invited ten CRC experts based on major scientific contribu-
tion in the field. The purpose of this paper was to define
current ‘‘state of the art’’ using the methodology of evidence-
based medicine. The available medical literature was
reviewed according to main topics of disease management,
and classified by scientific levels of evidence and grades of
clinical recommendation (Table 1) [2]. The resulting text
was reviewed, discussed, and approved by all authors.
Diagnosis and staging
The extent of the disease must be carefully assessed, as
well as tumor biology and patient-related factors before
starting cancer-specific therapy. A multidisciplinary team
will aim to identify patients with metastatic colorectal
cancer (mCRC) for which potentially curative surgical
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options are appropriate. The suggested procedures are
shown in Table 2. The recommended staging system is the
7th edition of the American Join Committee on Cancer’s
(AJCC) Cancer Staging [3].
Prognostic classifications
Prognosis of patients treated with modern chemotherapy
combinations depends, at a minimum, on clinical charac-
teristics (performance status—PS, comorbid conditions,
number, and site of metastases), BRAF mutational status
[4], and laboratory parameters (Table 2), with a median
survival ranging from 14 to 30 months.
The European Society of Medical Oncology (ESMO)
proposes assigning patients to one of 4 groups to guide
first-line therapeutic strategies (V, C). Group 0 are those
patients with liver or lung metastases suitable for poten-
tially curative resection (with clear margins, R0). Group 1
are those patients with limited liver and/or lung metastases
that are not R0-resectable upfront but might become
resectable after chemotherapy. Patients must be able to
undergo major surgery to belong to groups 0 and 1. Group
2 includes those patients with multiple metastasis that
present rapid progression and/or tumor-related symptoms
and/or risk of rapid deterioration. Patients must be able to
tolerate intensive chemotherapy to belong to groups 1 and
2. Those patients that will never have an option for
Table 1 Levels of evidence and grades of recommendation [2]
Levels of evidence:
I. Evidence from at least one large randomized, controlled trial of good methodological quality (low potential for bias) or meta-analyses of
well-conducted randomized trials without heterogeneity
II. Small randomized trials or large randomized trials with a suspicion of bias (lower methodological quality) or meta-analyses of such trials
or of trials with demonstrated heterogeneity
III. Prospective cohort studies
IV. Retrospective cohort studies or case–control studies
V. Studies without control group, case reports, experts opinions
Grades of recommendation
A. Strong evidence for efficacy with a substantial clinical benefit, strongly recommended
B. Strong or moderate evidence for efficacy but with a limited clinical benefit, generally recommended
C. Insufficient evidence for efficacy or benefit does not outweigh the risk or the disadvantages (adverse events, costs,…), optional
D. Moderate evidence against efficacy or for adverse outcome, generally not recommended
E. Strong evidence against efficacy or for adverse outcome, never recommended
Table 2 Suggested staging procedures
History including familial history of tumors and syndromes associated with hereditary disease
Physical examination must include the general condition (performance status, PS), and digital rectal exam
Laboratory tests including liver and renal function and prognostic markers (white blood cell count, alkaline phosphatase, lactate
dehydrogenase (LDH), bilirubin, and albumin)
Carcinoembryonic antigen (CEA)
Pathological review of a tumor biopsy should at least provide histological subtype, tumor grade, and KRAS and NRAS mutational status.
BRAF genotyping may be considered in RAS wild-type tumors for prognostic information
Computed tomography (CT) scan of the chest, abdomen and pelvis. Magnetic resonance imaging (MRI) of the liver could be considered in
cases of hepatic metastases
Complete colonoscopy to locate the primary tumor, to obtain tissue for histological diagnosis, and to detect potential synchronous colorectal
lesions. Virtual colonoscopy could be useful in case of tumors that impede the progression of the endoscopic tube
Other tests such as a bone scan or a brain CT scan should be performed only if clinically indicated
Additional examinations, as clinically needed, are recommended prior to major abdominal or thoracic surgery with potentially curative intent
Abdominal MRI with intravenous contrast may be considered in patients with potentially resectable liver metastases and for patients with
iodine allergy
A fluorodeoxyglucose (FDG)-positron emission tomography (PET–CT) scan should be performed, if available, when metastatic disease is or
may potentially become resectable
Needle biopsy of a patient with known histologic diagnosis is only recommended when it may change the therapeutic strategy
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resection, without major symptoms or risk of rapid dete-
rioration or that have severe comorbidity impeding inten-
sive chemotherapy treatment, belong to group 3 [5].
Biomarkers
Unfortunately, no useful predictive biomarkers have been
identified for any chemotherapy or anti-angiogenic drug in
mCRC. In contrast, activating mutations in KRAS exons 2,
3, and 4 and in NRAS exons 2, 3, and 4 have been identified
as biomarkers of intrinsic cancer cell resistance to cetux-
imab or panitumumab [6]. As a result, the European
Medicines Agency (EMA) has restricted the use of these
drugs to mCRC patients with KRAS and NRAS wild-type
(WT) tumors. No clearly standardized procedures for
KRAS/NRAS mutational testing have been established and
an increasing number of quantitative and highly sensitive
techniques are being used [7]. High sensitivity dPCR and
NGS platforms are able to pick up circulating tumor RAS
mutations and other molecular alterations in plasma that
drive primary or acquired resistance during anti-epidermal
growth factor receptor (EGFR) treatment [8, 9]. All the
studies from randomized trials that have validated the
predictive value of RAS mutations have been performed
with available archived paraffin tumor samples, from
recent or old primary tumors or metastasis indistinctively,
as there is little tumor heterogeneity when evaluating dif-
ferent tumor or metastases locations from the same indi-
viduals [10]. More variability has been found in mutation
calls from different labs in quality assessment audits [11].
Therefore, the expanded RAS mutation analysis needs to be
known before anti-EGFR treatment in mCRC, performed
on tumor DNA from any location, as long as the per-
forming lab complies with nationally or internationally
qualified quality assurance programs (I, A). Plasma can be
a surrogate source tissue for mutational analysis when no
tumor sample is available or for testing secondary resis-
tance (III, C) (Table 3).
Role of surgery
Palliative resection for patients with symptomatic primary
tumors is mandatory. In patients with an asymptomatic
primary tumor and unresectable metastasic disease, pri-
mary tumor surgery is controversial. A meta-analysis
showed no benefit in survival and quality of life with
colectomy in this setting. It is also associated with higher
mortality and morbidity rates than in earlier stages, and
only 10–20 % patients will present complications requiring
surgical treatment [12]. Patients with asymptomatic pri-
mary tumor and unresectable disease should start initial
palliative chemotherapy. Resection of the primary tumor
should only be performed in patients who develop serious
complications (II, B).
Surgical resection of colorectal liver metastases
(CRLM) is a potentially curative treatment with 5-year
survival rates of 20–50 %, but it is only feasible in\15 %
of patients. The criteria for resectability of CRLM depend
on the experience of the multidisciplinary expert team.
Technical aspects like the possibility of all viable tumor to
be removed with negative margins while leaving sufficient
functional remnant liver ([30 %), and the presence of
resectable extrahepatic disease must be considered [13].
Known prognostic factors are laboratory parameters
(Table 2), number of metastases, size and location of the
lesions, disease-free interval and lymph node stage (for
metachronous metastases), tumor grade, and satellite
metastases [14]. Resection of lung metastases also offers
25–35 % 5-year survival rates in carefully selected
patients. Surgical R0 resection should be performed for
solitary or confined liver or pulmonary metastases (II, A).
Peritoneal carcinomatosis (PC) from CRC may occur in
up to 50 % of patients. Cytoreductive surgery (CS) with
hyperthermic intraperitoneal chemotherapy (HIPEC) con-
sists on performing radical surgery of all visible tumor in
the abdomen followed immediately by HIPEC which acts
on microscopic residual tumor. One phase III trial and
numerous phase II trials with CS ? HIPEC suggest
improved survival of selected patients with isolated PC
from CRC origin, with 5-year survival rates of 30–50 %
[15]. CS and HIPEC by experienced expert teams may
improve progression-free survival (PFS) and overall sur-
vival (OS) for selected patients with PC (IV, B).
First-line systemic treatment: chemotherapy
Cytotoxic chemotherapy represents the basis for medical
treatment of mCRC. Compared to 5-fluorouracil (5-FU)
alone, combinations are more effective but also more toxic
[16, 17]. Irinotecan is associated with neutropenia, alopecia,
and gastrointestinal side effects (nausea, vomiting, diarrhea,
and mucositis). Oxaliplatin-based combinations are associ-
ated with neutropenia, thrombocytopenia, diarrhea and
sensory neuropathy, and the main dose-limiting toxicity.
Infusional 5-FU schedules are less toxic than bolus regimens
and should preferably be used. Combinations of bolus 5-FU
with either irinotecan or oxaliplatin are not recommended
based on higher toxicity and poor outcomes [18]. For most
patients with good PS status and no significant comorbidi-
ties, the combination of infused regimens of 5-FU/leucov-
orin (LV) with either oxaliplatin (FOLFOX) or irinotecan
(FOLFIRI) remains the recommended chemotherapy back-
bone for first-line treatment (I, A).
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Several direct comparisons of the addition of oxaliplatin
versus irinotecan to a LV/5-FU regimen did not show any
difference in first-line therapy in terms of response rate
(RR) and PFS [19, 20]. Thus, first-line chemotherapy
selection should be based on prior oxaliplatin-based adju-
vant treatment, clinical conditions and comorbidities, bio-
logic drug to be combined, and patient’s preferences.
Capecitabine is an oral fluoropyrimidine (FP) with
similar efficacy to bolus 5-FU/LV in the first-line treatment
of mCRC [21]. The most common adverse events are
gastrointestinal (diarrhea, nausea, vomiting, and stomatitis)
and hand-foot syndrome. Capecitabine in combination with
oxaliplatin is considered to have an efficacy (PFS and OS)
similar to that of FOLFOX [22]. Thus, the oxaliplatin and
capecitabine combination is an alternative first-line treat-
ment option for patients with mCRC (I, B). Toxicity with
capecitabine and irinotecan combinations is higher, mainly
gastrointestinal.
Retrospective analysis indicates that the use of all three
cytotoxics (FP, oxaliplatin, and irinotecan) in various
sequences may result in the longest survival [23]. However,
some evidences suggest that initial polychemotherapy is not
essential in all cases [24, 25]. In selected patients (i.e., with
unresectable, low burden disease, slow tumor growth, mild
Table 3 Summary of recommendations
The European Society of Medical Oncology (ESMO) proposes assigning patients to one of 4 groups to guide first-line therapeutic strategies
(V, C)
The expanded RAS mutation analysis needs to be known before anti-EGFR treatment in mCRC, performed on tumor DNA from any location,
as long as the performing lab complies with nationally or internationally qualified quality assurance programs (I, A)
Plasma can be a surrogate source tissue for mutational analysis when no tumor sample is available or for testing secondary resistance (III, C)
Patients with asymptomatic primary tumor and unresectable disease should start initial palliative chemotherapy. Resection of the primary
tumor should only be performed in patients who develop serious complications (II, B)
Surgical R0 resection should be performed for solitary or confined liver or pulmonary metastases (II, A)
CS and HIPEC by experienced expert teams may improve progression-free survival (PFS) and overall survival (OS) for selected patients with
PC (IV, B)
For most patients with good PS status and no significant comorbidities, the combination of infused regimens of 5-FU/leucovorin (LV) with
either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) remains the recommended chemotherapy backbone for first-line treatment (I, A)
First-line chemotherapy selection should be based on prior oxaliplatin-based adjuvant treatment, clinical conditions and comorbidities,
biologic drug to be combined, and patient’s preferences
Oxaliplatin and capecitabine combination is an alternative first-line treatment option for patients with mCRC (I, B)
In selected patients (i.e., with unresectable, low burden disease, slow tumor growth, mild symptoms, or frailty) a sequential therapy starting
with FP or FP plus bevacizumab could be a valid option (I, B) [26–28]
Anti-EGFR antibodies should not be used without prior determination of RAS status. Expanded RAS analysis is superior to conventional RAS
analysis (I, A)
Addition of anti-EGFR therapy to FOLFIRI and to FOLFOX improves PFS and OS in first-line treatment of patients with mCRC (II, A)
The addition of bevacizumab to chemotherapy is beneficial with respect to chemotherapy alone (I, B)
There is no clear evidence of the superiority of anti-EGFR over bevacizumab in combination with chemotherapy in the first-line treatment of
mCRC
Anti-EGFR agents should not be combined with bevacizumab (I, B)
First-line treatment for fit patients with WT RAS mCRC should include a combination of chemotherapy doublet and a monoclonal antibody
(anti-EGFR or bevacizumab)
First-line treatment for fit patients with mutant RAS mCRC should include a combination of chemotherapy doublet and bevacizumab (I, B)
Second and successive treatment lines should be individualized according to prior therapy, RAS status and clinical condition (II, C)
Patients with completely resected metastases should receive perioperatively 6 months of an active, preferably oxaliplatin-based chemotherapy
regimen (I, B)
Fit patients with borderline resectable metastases should receive intensive induction therapy with chemotherapy doublets and a monoclonal
antibody, or chemotherapy triplets with or without bevacizumab. In RAS WT tumors, anti-EGFR may be more effective than bevacizumab
in terms of tumor shrinkage (II, B)
Fit patients with technically unresectable metastases and bulky, symptomatic or biologically aggressive disease, should receive intensive first-
line therapy with chemotherapy doublets and a monoclonal antibody. In RAS WT tumors, bevacizumab may be subjectively better tolerated
and allow the patient to receive more lines of therapy. Anti-EGFR agents, however, may be preferred in patients with significant tumor-
related symptoms (IV, B)
Treatment de-escalation after induction therapy is often required due to cumulative toxicity, and is also acceptable once disease control is
achieved (II, B)
Patients with unresectable metastases who are either unfit or asymptomatic and have limited risk for rapid clinical deterioration, should
receive non-intensive/sequential therapy (I, B)
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symptoms, or frailty) a sequential therapy starting with FP or
FP plus bevacizumab could be a valid option (I, B) [26–28].
One randomized phase III trial showed increased RR,
resectability of metastases ,and survival with the FOLFOXIRI
combination, at the expense of higher toxicity [29]. The
combination of bevacizumab and FOLFOXIRI has shown to
significantly improve RR and PFS in selected mCRC patients
when compared to FOLFIRI plus bevacizumab, again with
increased incidence of adverse events [30].
First-line systemic treatment: targeted therapies
First-line targeted therapies include the anti-vascular
endothelial growth factor (VEGF) agent bevacizumab and
the anti-EGFR agents, cetuximab and panitumumab. RAS
status is the main factor involved in the decision about anti-
VEGF or anti-EGFR strategy [31, 32]. Anti-EGFR anti-
bodies should not be used without prior determination of
RAS status. Expanded RAS analysis is superior to conven-
tional RAS analysis (I, A).
Management of patients with wild-type (WT)
mCRC after expanded RAS analysis
The CRYSTAL trial compared FOLFIRI versus FOLFIRI
with cetuximab in first-line mCRC. The cetuximab-con-
taining arm provided benefits in OS, PFS, and RR in RAS
WT patients [31]. The PRIME trial compared the combi-
nation of FOLFOX4 versus FOLFOX4 ? panitumumab in
previously untreated mCRC. In the RAS expanded analysis,
PFS and OS were more favorable for the combination
group [32]. Some studies suggest that antiEGFR agents
should not be combined with oxaliplatin-based, non-infu-
sional FP schedules. Addition of anti-EGFR therapy to
FOLFIRI and to FOLFOX improves PFS and OS in first-
line treatment of patients with mCRC (II, A). Randomized
trials have also demonstrated improved PFS and/or OS
when bevacizumab is added to irinotecan-, oxaliplatin-,
and FP-based chemotherapy [26–28, 33, 34]. The addition
of bevacizumab to chemotherapy is beneficial with respect
to chemotherapy alone (I, B). After analysis of expanded
RAS mutations, RR and median OS were better for FOL-
FIRI plus cetuximab compared to FOLFIRI plus beva-
cizumab in the FIRE-3 trial [35]. Schwartzberg et al. [36]
compared mFOLFOX6 plus panitumumab or bevacizumab
in a randomized phase II trial. In the RAS WT subgroup,
PFS and median OS were greater for the panitumumab
arm. The phase III CALGB/SWOG 80405 study evaluated
the combination of FOLFIRI or mFOLFOX6 with beva-
cizumab or cetuximab [37]. After a preliminary analysis of
expanded RAS mutations, no differences in median PFS
and OS have been found. A meta-analysis of the three
studies showed an increase in RR and OS with first-line
anti-EGFR therapy compared with anti-VEGF therapy in
RAS WT mCRC [38]. There is no clear evidence of the
superiority of anti-EGFR over bevacizumab in combina-
tion with chemotherapy in the first-line treatment of
mCRC. Two randomized trials have demonstrated that
combination of chemotherapy with both anti-EGFR and
bevacizumab is deleterious [39, 40]. Anti-EGFR agents
should not be combined with bevacizumab (I, B). First-line
treatment for fit patients with WT RAS mCRC should
include a combination of chemotherapy doublet and a
monoclonal antibody (anti-EGFR or bevacizumab).
Management of patients with mutated mCRC
after expanded RAS analysis
As aforementioned, the addition of bevacizumab to
irinotecan-, oxaliplatin-, or FP-based chemotherapy is
beneficial in comparison with the administration of
chemotherapy alone, independently of the RAS status.
However, the addition of anti-EGFR therapies has a
potential detrimental effect in RAS-mutated patients. First-
line treatment for fit patients with mutant RAS mCRC
should include a combination of chemotherapy doublet and
bevacizumab (I, B).
Second- and successive treatment lines
Therapy after first progression will depend on prior treat-
ments (Figs. 1, 2, 3). For patients who received oxaliplatin-
based therapy, FOLFIRI, or irinotecan alone are the pre-
ferred options. When the previous treatment was an
irinotecan-based combination, the recommended options
are FOLFOX or XELOX. With respect to the use of tar-
geted therapies, available options are as follows:
– For patients treated with first-line bevacizumab-con-
taining chemotherapy, the continuation of bevacizumab
in conjunction with a second-line chemotherapy
improves OS [41] and PFS [41, 42] as compared to
just switching the chemotherapy regimen alone.
– It may also be appropriate adding bevacizumab to
chemotherapy if it was not used in initial therapy,
preferably in combination with oxaliplatin-based ther-
apy [43].
– For patients previously treated with oxaliplatin-based
therapy, FOLFIRI plus aflibercept is an option, partic-
ularly if they did not receive prior bevacizumab therapy
[44].
– Other alternative after progression to FOLFOX plus
bevacizumab in first line is FOLFIRI plus ramucirumab
[45].
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– For patients with expanded RAS WT mCRC, cetux-
imab, or panitumumab plus preferably irinotecan-based
therapy [46, 47] is recommended in second-line
treatment. They may also be employed as single agents
in third or subsequent lines of therapy in patients naive
of anti-EGFR therapy [48, 49]. Cetuximab and panitu-
mumab appear to have comparable efficacy when used
as single agents for salvage therapy in patients with
chemotherapy-refractory mCRC [50]. The reintroduc-
tion of EGFR inhibitors in subsequent treatment lines is
not recommended for previously exposed patients.
Regorafenib [51] and TAS 102 [52] may be considered
for patients who have progressed to all three chemothera-
peutic drugs, bevacizumab and anti-EGFR agents, that still
conserve adequate PS and organ function.
Second and successive treatment lines should be indi-
vidualized according to prior therapy, RAS status, and
clinical condition (II, C).
Treatment strategy
As treatment options continue to expand for mCRC,
selection of the most appropriate therapeutic regimen and
administration sequence, as well as their integration with
other treatment modalities (i.e., surgery or ablative thera-
pies), is becoming increasingly complex. Since the choice
of first-line treatment will compromise subsequent treat-
ment options, it is important to plan upfront a temptative
therapeutic strategy, particularly in those patients with
unresectable disease, within the concept of the continuum
of care. Some practical recommendations to tailor the
therapeutic strategy according to the four clinically defined
groups by ESMO are provided below [5]. Suggested
treatment sequence is shown in Figs. 1, 2, and 3 [53].
Group 0
In patients with resectable metachronous metastasis, peri-
operative chemotherapy with FOLFOX has shown to
modestly improve disease-free survival (DFS) with a non-
significant trend towards improved survival. Initial resec-
tion of metastases followed by adjuvant chemotherapy is
an alternative option. In patients with resectable syn-
chronous metastases, integration of the surgical strategy
with perioperative chemotherapy shall be carefully cus-
tomized in each patient considering location of primary
tumor and metastasis, their size and extent, local symp-
toms, patient’s comorbid conditions, and the expected liver
remnant after resection. Preoperative chemotherapy
Front line oxaliplatin Second line Third line
FOLFOX -BV 
or
XELOX - BV
FOLFIRI
FOLFIRI + antiangiogenic
If RAS wt:
- Irinotecan + antiEGFR 
- If not able to tolerate former: 
Monotherapy with antiEGFR
If RAS mutated
- Regorafenib/TAS102*
- Clinical trials or 
- Best supportive care
FOLFOX-antiEGFR
(only RAS wt) FOLFIRI +/- antiangiogenic
Regorafenib/TAS102*
Clinical trials or 
Best supportive care
FOLFIRI + antiEGFR (only RAS wt)
Irinotecan + antiEGFR (only RAS wt)
Regorafenib/TAS102*
Clinical trials or 
Best supportive care
Fourth line
Regorafenib/TAS102*
Clinical trials or 
Best supportive care
Fig. 1 Therapeutic strategies in advanced colorectal cancer. Patients
appropriate for intensive therapy. Note Front line treatment should
consider clinical symptoms, comorbid conditions, prior adjuvant
therapy, tumor biology and dynamics, and potential ability for
metastasis resection. BV bevacizumab, XELOX oxali-
platin ? capecitabine, FOLFOX biweekly oxaliplatin ? infusional
5FU/LV, FOLFIRI biweekly irinotecan ? infusional 5FU/LV, wt
wild type. *If available
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Front line Irinotecan Second line Third line
FOLFIRI - BV
If RAS mutated:
- FOLFOX +/- BV
- Regorafenib/TAS102*
- Clinical trials or 
- Best supportive care
Fourth line
Regorafenib/TAS102*
Clinical trials or 
Best supportive care
FOLFIRI-anitEGFR
(only RAS wt)
FOLFOX +/- antiangiogenic
XELOX +/- antiangiogenic
Regorafenib/TAS102*
Clinical trials or 
Best supportive care
antiEGFR 
Regorafenib/TAS102*
Clinical trials or 
Best supportive care
If RAS wt::
- FOLFOX +/- BV
- Irinotecan + antiEGFR 
Fig. 2 Therapeutic strategies in advanced colorectal cancer. Patients
appropriate for intensive therapy. Note Front line treatment should
consider clinical symptoms, comorbid conditions, prior adjuvant
therapy, tumor biology and dynamics, and potential ability for
metastasis resection. BV bevacizumab, XELOX oxali-
platin ? capecitabine, FOLFOX biweekly oxaliplatin ? infusional
5FU/LV, FOLFIRI biweekly irinotecan ? infusional 5FU/LV, wt
wild type. *If available
Second lineFirst line
Infusional 5FU/LV +/-BV
Capecitabine +/- BV
Irinotecan
Candidate for therapy
but still frail
Improvement in functional
status
Functional status 
deteriorates
Consider priorly described
CT regimens for fit patients
Best supportive care
Third line
Irinotecan and/or antiEGFR*
Infusional 5FU/LV
Capecitabine 
(depending on 1st line choice)
AntiEGFR*and/or irinotecan
(if not priorly given)
Regorafenib/TAS102+
Clinical trials or 
Best supportive care
Fig. 3 Therapeutic strategies in advanced colorectal cancer in patients who cannot tolerate intensive therapy. BV bevacizumab, 5FU/LV
5-fluorouracil/leucovorin, CT chemotherapy. *RAS wild type only. ?If available
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followed by synchronous or staged colectomy and liver or
lung resection may be considered. Colectomy may be
followed by neoadjuvant chemotherapy and a staged
resection of metastatic disease, or may be performed with
synchronous or subsequent liver or lung resection, fol-
lowed by post-operative chemotherapy. Patients with
completely resected metastases should receive periopera-
tively 6 months of an active, preferably oxaliplatin-based
chemotherapy regimen (I, B).
Ablative therapy of liver metastases using radiofre-
quency, cryosurgery, or external radiotherapy (radio-
surgery, SBRT, and IMRT) is an alternative strategy if
surgical resection is not technically feasible or medically
advisable [54].
Group 1
In patients with initially unresectable, organ-confined
metastases, systemic chemotherapy may induce sufficient
cytoreduction to enable subsequent resection. The achieve-
ment of a disease-free status is a highly desirable goal and the
only means for the patient to potentially achieve long-term
survival. With this aim, the most active induction regimens
shall be administered upfront in patients able to tolerate it,
generally chemo-doublets combined with a monoclonal
antibody or chemo-triplets. Different combinations of either
oxaliplatin or irinotecan with FP are considered suit-
able chemotherapy options with similar efficacy but different
toxicity profiles. Cross-trial comparisons and prospectively
planned subgroup analysis from the FIRE-3 trial suggest that
anti-EGFR agents may be more effective in terms of tumor
shrinkage than bevacizumab combinations [35–38]. Triplet
combination with FOLFOXIRI, with or without beva-
cizumab, may be also considered in selected patients [29,
30]. Anyway, potential conversion to resectability has to be
reevaluated every 2 months and surgery scheduled as soon as
possible, to minimize chemotherapy-induced liver toxicities
and perioperative morbidity. Fit patients with borderline
resectable metastases should receive intensive induction
therapy with chemotherapy doublets and a monoclonal
antibody, or chemotherapy triplets with or without beva-
cizumab. In RAS WT tumors, anti-EGFR may be more
effective than bevacizumab in terms of tumor shrinkage
(II, B).
Group 2
In patients with technically unresectable metastasis but
adequate PS, and bulky, symptomatic or biologically
aggressive disease, intensive first-line therapy is advised
aiming to induce early tumor regression/control and/or
symptomatic relief. A chemotherapy doublet in combi-
nation with a targeted agent is generally recommended
for these patients (Figs. 1, 2). Upfront bevacizumab-
based therapy would provide patients more treatment
options in the long run, allowing EGFR-targeted agents
to be used later in the course of the disease. However,
first-line therapy with anti-EGFR monoclonal antibodies
is also a reasonable option in patients with RAS WT
tumors, particularly in those with significant tumor-re-
lated symptoms due to the earlier onset of response
induced by these agents. Fit patients with technically
unresectable metastases and bulky, symptomatic, or
biologically aggressive disease, should receive intensive
first-line therapy with chemotherapy doublets and a
monoclonal antibody. In RAS WT tumors, bevacizumab
may be subjectively better tolerated and allow the patient
to receive more lines of therapy. Anti-EGFR agents,
however, may be preferred in patients with significant
tumor-related symptoms (IV, B).
Maintenance treatment with FP and bevacizumab has
been shown to prolong PFS with no impact on OS as
compared to complete discontinuation of therapy. Treat-
ment de-escalation after induction therapy is often required
due to cumulative toxicity, and is also acceptable once
disease control is achieved (II, B).
Group 3
Patients with definitively unresectable disease, unfit due to
comorbid conditions, and/or with no present or imminent
symptoms and limited risk for rapid deterioration, are
good candidates for non-intensive therapy. The therapeutic
aim in these patients is to slow tumor progression and
improve life expectancy with minimum treatment burden.
Initial FP monotherapy is a common upfront treatment
option in these patients, with or without bevacizumab
(Fig. 3). Irinotecan or raltitrexed may also be suitable op-
tions for patients in whom FP are not warranted (i.e.,
severe vascular disease, DPD deficient). If functional
status improves following therapy, more intensive thera-
peutic strategies may be considered. If health status
deteriorates, best supportive care is the recommended
option. If the patient is still frail but candidate for further
therapy upon disease progression to FP, irinotecan may be
administered, either alone or, in RAS WT tumors, in
combination with EGFR-targeted agents. Cetuximab or
panitumumab may be also employed as single agents in
patients with progressive disease after prior irinotecan-
based treatment. Patients with unresectable metastases
who are either unfit or asymptomatic and have limited risk
for rapid clinical deterioration, should receive non-inten-
sive/sequential therapy (I, B).
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